PULSE the living trend engine
🤖 Open Intelligence Dossier available for AI agents & citation View Markdown (.md) →
◼ Archived Business 🔮 PULSE predicts: fades by tomorrow

Takeda’s TYK2 inhibitor beats Bristol Myers’ Sotyktu in phase 3 psoriasis showdown

5 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.

5sources
5articles
3velocity
+0%since first seen
135d agofirst detected

Velocity

How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →

The brief

"Takeda’s TYK2 inhibitor beats Bristol Myers’ Sotyktu in phase 3 psoriasis showdown" is generating significant coverage in the Business category, with 5 articles from 5 distinct sources tracked by PULSE so far.

Outlets currently covering the story include FirstWord Pharma, Endpoints News, Business Wire and BioPharma Dive. PULSE measures a story's velocity from how quickly new articles appear and how many independent newsrooms join the coverage.

This brief was generated by PULSE's extractive engine from coverage metadata only. The latest headlines from every source are listed below; the velocity chart shows how the story is developing in real time.

Generated by PULSE's extractive engine from coverage metadata only — no AI-written claims. Updated 112d ago.

Quick answers

Why is "Takeda’s TYK2 inhibitor beats Bristol Myers’ Sotyktu in phase 3 psoriasis showdo" trending?

Because 5 independent news sources published 5 articles about it in a short window — a coverage burst PULSE classifies as a trend.

How does PULSE measure this trend?

PULSE scores velocity from the rate of new articles weighted by source diversity, snapshotted hourly. The full method is public on our methodology page.

Is this trend still active?

The status badge on this page updates hourly: rising, peaking, cooling, or archived once coverage stops for 48 hours.

Coverage (5)

Topics

Takeda TYK2 Bristol Myers Sotyktu

Related trends

\n \n \n \n \n \n \n